1.
纳入研究的基本特征
The general characteristics of included studies
| Included studies | Nation (study type) | Cases | Clinicopathological staging | Radiotherapy | Pathological types |
| SCC: squamous cell carcinoma; AD: adenocarcinoma; LC: large cell carcinoma; NSCLC NOS: non-small cell lung cancer not otherwise specified; CGE: cobalt Gray equivalent; NR: not reported. | |||||
| Jiang 2006[7] | China (clinical control study) | 5 | NR | 60 Gy/60 CGE | AD: 1 SCC: 3 Unknown: 1 |
| Chang 2006[8] | America (clinical control study) | 25 | Stage Ⅰ：10 Stage Ⅲ：15 |
Phase Ⅰ: 66 Gy, 87.5 CGE Phase Ⅲ: 63 Gy, 74 CGE |
NR |
| Wang 2009[9] | Japan (clinical control study) | 24 | Stage Ⅰ Ⅰa: 16 Ⅰb: 16 |
66 Gy/60 CGE | AD: 16 SCC: 6 Others: 2 |
| Georg 2008[10] | Australia (clinical control study) | 12 | NR | 45 Gy/3 f | NR |
| Register 2011[11] | America (clinical control study) | 15 | Stage Ⅰ：15 | 50 Gy/4 f | NSCLC NOS: 15 |
| Roelofs 2012[12] | America, Norway, Canada (multicenter clinical control study) | 25 | Stage Ⅰ：4 Stage Ⅱ：3 Stage Ⅲ：18 |
70 Gy/70 CGE | AD: 5 SCC: 7 LC: 11 NSCLC NOS: 2 |